BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Almost all cases of ALS and half of frontotemporal dementia (FTD) cases are linked to dysfunction in a protein TDP-43.

The stock of Eli Lilly and Company LLY has declined 10.6% in a month ... Lilly is also making rapid pipeline progress in ...

Britain’s National Health Service (NHS) has announced that it will not cover Eli Lilly’s new Alzheimer’s drug, donanemab.

They are expected to act as a catalyst in medicine, society, the economy, and even in... fuel consumption - The astounding ...

AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - September 2024 is now available on the company's ...

STOCKHOLM, SE / ACCESSWIRE / November 11, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - Septem ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

We recently published a list of 10 Best Stocks to Buy According to Billionaire Ken Fisher. In this article, we are going to ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

These doctors live for innovation in Alzheimer's drug discovery and they want to be involved ... One CTAD presentation ...

Being started on a smaller dose of the approved early Alzheimer’s therapy Kisunla was found to reduce the risk of ARIA-E on imaging scans.